These changes in OXPHOS have implications for tumor growth and potential therapeutic targets, including the development of selective HIF-2α antagonists, which have demonstrated clinical efficacy in treating ccRCC (55). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.